Glucagon: Structure, Biosynthesis and Physiological Effects

$110.00

Ahmed Al-Jebawi (Editor)
Clinical Assistant Professor, Indiana University School of medicine, Chairman, Physician Training Program, Dubai Diabetes Center, Dubai, United Arab Emirates

Series: Endocrinology Research and Clinical Developments
BISAC: MED027000

Since the discovery of the glucagon hormone, our knowledge of the pathophysiological changes of glucose metabolism has increased substantially. One of the first major breakthroughs in our understanding of the pathogenesis of diabetes occurred when patients with diabetic ketoacidosis were found to have very high glucagon levels. Since then, more observations confirmed hyperglucagonemia in diabetic patients. Despite the vast knowledge that we gained on glucagon, treating people with diabetes remained limited to replacing insulin, stimulating its secretion or improving its action for many years.

Targeting glucagon pathway was not thought of as a valuable approach to treating diabetes until the first incretin mimetic was proved to be highly effective for not only stimulating the secretion of insulin but also for suppressing the glucagon secretion. The concept of bi-hormonal abnormality has changed the way we approach and treat diabetes. This book represents an extended and thorough review of glucagon biosynthesis and physiological effects. It also outlines the therapeutic options currently available to treat glucagon metabolic disorders. As it is intended for the whole scientific community, the material included was selected to be both clinical and scientific. It offers a unique integrative approach combining the expertise of the different specialties of endocrinology, physiology, cell biology, diabetes genetics and diabetes education. (Imprint: Nova Biomedical )

Clear

Details

Table of Contents

Preface

Chapter 1: History of Glucagon and GLP-1
(Alaaeldin Bashier and Puja Murli Thadani, Endocrine Division-Medical Department, Dubai Hospital, United Arab Emirates)

Chapter 2: Glucagon Structure, Secretion and Function
(Ahmed F. Al-Jebawi, Indiana University School of Medicine Indianapolis, IN, USA and others)

Chapter 3: Physiological Effects of Glucagon on Cardiovascular System
(M.A. Rosic, V. Zivkovic, S. Pantovic, M. Colic and VLj Jakovljevic, Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia)

Chapter 4: The Role of Abnormal Glucagon in Type 2 Diabetes
(Ahmed F. Al-Jebawi, Indiana University School of Medicine Indianapolis, IN, USA and others)

Chapter 5: The Role of Incretin Hormones in Glucagon Regulation and Diabetes Treatment
(Shushan B. Artinian, Sawsan M. Al-Lafi, Suzan S. Boutary, Nadine S. Zwainy and Anwar B. Bikhazi, Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon)

Chapter 6: Glucagon Antagonists
(Alaaeldin M.K. Bashier and Puja Murli Thadani, Endocrine Division-Medical Department, Dubai Hospital, United Arab Emirates)
<a href=”https://novapublishers.com/wp-content/uploads/2019/08/978-1-62618-147-2_ch6.pdf” target=”_blank” rel=”noopener”>Free Download Available</a>

Chapter 7: Alpha-Cell-Mediated Beta-Like Cell Regeneration as a Putative Therapeutic Pathway For Type 1 Diabetes
(Anja Pfeifer, Keith Al-Hasani, Monica Courtney, Nouha Ben-Othman, Elisabet Gjernes, Andhira Vieira and Patrick Collombat, INSERM U636, Diabetes Genetics Team, FR-06108 Nice, France, and others)

Chapter 8: Glucagon: Improving Knowledge and Education on the Antidote to Severe Hypoglycemia
(B. Sommavilla, University Hospital, Center for Prevention and Care, Salzburg, Austria)

Index

Additional information

Binding

,